Royal Bank Of Canada Longeveron Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.25 - $2.51 $73 - $148	59 Added 80.82%	132 $0
Q3 2023 Nov 14, 2023	SELL	$2.15 - $3.59 $30 - $50	-14 Reduced 16.09%	73 $0
Q2 2023 Aug 14, 2023	BUY	$2.52 - $4.0 $219 - $348	87 New	87 $0
Q3 2022 Nov 14, 2022	BUY	$3.97 - $42.7 $214 - $2,305	54 New	54 $0
Q1 2022 May 16, 2022	SELL	$5.06 - $13.8 $35 - $96	-7 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.92 - $42.3 $20 - $296	7 New	7 $0
Q3 2021 Nov 15, 2021	SELL	$3.4 - $8.3 $11,900 - $29,050	-3,500 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$5.2 - $8.13 $18,200 - $28,455	3,500 New	3,500 $28,000

1.18K

Ticker LGVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,925,940
Market Cap $11.2M
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.